As cancer patients can acquire DM1 resistance due to DM1′s compatibility with the membrane drug transporter and the consequent increased efflux of DM1 from cells, TOP1 inhibitors are arising as potent drugs for cancer patients who have developed resistance to drugs that are substrates for the membrane drug transporter [24]. Here, TOP1 is linked to cancer.